Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001373604-25-000020·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, $0.00001 par value per share · CUSIP: 037326105
Event date: 2024-12-31
- Filing-level shares
- 5,749,432
- Percent of class
- 19.2%
- BML Investment Partners, L.P.
Shares: 5,749,432 · Class: 19.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001373604-25-000020
- Form type
- SCHEDULE 13G/A
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership